Active, not recruitingPhase 3NCT01892722

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Studying Pediatric multiple sclerosis

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Novartis Pharmaceuticals
Principal Investigator: Novartis Pharmaceuticals
Novartis Pharmaceuticals
Intervention: Interferon beta-1a(drug)
Enrollment: 240 enrolled
Eligibility: 10-17 years · All sexes
Timeline: 2013 – 2030

Study locations (30)

UAB Childrens Hospital Harbor Center Neurology Dept, Birmingham, Alabama, United States
Childrens Hospital Los Angeles, Los Angeles, California, United States
UCSF, San Francisco, California, United States
University of Miami, Miami, Florida, United States
AMO Corporation, Tallahassee, Florida, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Wayne State University, Detroit, Michigan, United States
Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
University of Utah Clinical Trials Office, Salt Lake City, Utah, United States
Novartis Investigative Site, Parkville, Victoria, Australia
Novartis Investigative Site, Vienna, Austria
Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site, Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01892722 on ClinicalTrials.gov

Other trials for Pediatric multiple sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Pediatric multiple sclerosis →

← Back to all trials